Lactiga is an award-winning, venture-backed biotherapeutics company committed to restoring mucosal immunity in patients with rare immunodeficiency diseases. We are unlocking the full therapeutic value of IgA antibodies developed from human milk to create the next generation of anti-infectives to fight debilitating pathogens including SARS-CoV-2 and its variants.
Lactiga holds 3 granted patents in support of its LCTG-001 program to prevent life-threatening, respiratory mucosal infections in patients with immunodeficiencies like common variable immune deficiency (CVID) and its NIH-funded program LCTG-002 to develop an airway therapeutic to reduce hospitalizations and infections from COVID-19 and its variants in vulnerable populations.
Recurrent ear infections, sinusitis, pneumonia, and diarrhea are the most common symptoms in patients with Selective IgA Deficiency (SIgAD).
Respiratory and gastrointestinal infections, which are common in patients with Primary Immunodeficiency Diseases (PIDD).
They are large proteins, derived from a mother’s breastmilk, that bind and neutralize pathogens.
The novelty of our work is reflected in our granted US, Canadian and Japanese patents.
There are millions of immunodeficient patients of all ages worldwide, facing costly treatments and frequent hospitalizations.
If you’re a patient suffering from an antibody deficiency, we’d love to hear from you — your journey motivates our work. If you’re interested in investment or partnership opportunities, let’s have a discussion.
Lactiga, with offices in New Jersey and Toronto , is a biotechnology company focused on developing novel biologics to tackle even the most severe mucosal infections in immunodeficient patients.
Our technology targeting mucosal infections has the potential to address unmet medical needs in patients of all ages.
The scientific experts at Lactiga strive to deeply understand the immunodeficient patient perspective in order to improve their quality of life.
Our team expertise includes immunology, nanotechnology, genetics, pharmacology, and infectious disease.
Supported by committed investors, partners, and advisors, we have the resources in place to advance our development programs to market.
